Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Jaros

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 5, 2012
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trialsJesse M Cedarbaum, Mark Jaros, Chito Hernandez, et al.
NEJM Evidence|December 8, 2024
BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress DisorderSpyridon Papapetropoulos, Elizabeth Doolin, Susan O'Connor, et al.
Psychiatry Research|February 15, 2025
A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL studySpyros Papapetropoulos, Elizabeth Doolin, Michael Odontiadis, et al.
Clinical Pharmacology in Drug Development|January 3, 2025
Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System DiseasePaul Rolan, Jonathan Seckl, Jack Taylor, et al.
JAMA Ophthalmology|October 1, 2020
Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical TrialsCharles B Slonim, Shane Foster, Mark Jaros, et al.
Spine|October 30, 2013
Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniationBrian J C Freeman, Guy L Ludbrook, Stephen Hall, et al.
Spine|August 30, 2014
In responseBrian J C Freeman, Guy L Ludbrook, Stephen Hall, et al.
Frontiers in Medicine|January 6, 2022
CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective RegistryTae Song, Jeremiah Hayanga, Lucian Durham, et al.
The New England Journal of Medicine|March 19, 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolKausik K Ray, R Scott Wright, David Kallend, et al.
Journal of the American College of Cardiology|March 5, 2021
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or AtherosclerosisR Scott Wright, Kausik K Ray, Frederick J Raal, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 5, 2012
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trialsJesse M Cedarbaum, Mark Jaros, Chito Hernandez, et al.
NEJM Evidence|December 8, 2024
BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress DisorderSpyridon Papapetropoulos, Elizabeth Doolin, Susan O'Connor, et al.
Psychiatry Research|February 15, 2025
A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL studySpyros Papapetropoulos, Elizabeth Doolin, Michael Odontiadis, et al.
Clinical Pharmacology in Drug Development|January 3, 2025
Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System DiseasePaul Rolan, Jonathan Seckl, Jack Taylor, et al.
JAMA Ophthalmology|October 1, 2020
Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical TrialsCharles B Slonim, Shane Foster, Mark Jaros, et al.
Spine|October 30, 2013
Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniationBrian J C Freeman, Guy L Ludbrook, Stephen Hall, et al.
Spine|August 30, 2014
In responseBrian J C Freeman, Guy L Ludbrook, Stephen Hall, et al.
Frontiers in Medicine|January 6, 2022
CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective RegistryTae Song, Jeremiah Hayanga, Lucian Durham, et al.
The New England Journal of Medicine|March 19, 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolKausik K Ray, R Scott Wright, David Kallend, et al.
Journal of the American College of Cardiology|March 5, 2021
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or AtherosclerosisR Scott Wright, Kausik K Ray, Frederick J Raal, et al.
Pageof 3